![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
ORIGINAL ARTICLES
Minerva Psichiatrica 2003 December;44(4):201-6
Copyright © 2003 EDIZIONI MINERVA MEDICA
language: English
Therapeutic effects of clomipramine in endogenous depression. Personal experience
Ros L. T.
Aim. Clomipramine is an antidepressant drug with tricyclic structure, a dibenzoazepine derivative, and has been introduced to treatment by Kuhn in 1963. The onset of therapeutic action is observed usually after 7 days of drug administration.
Methods. Clomipramine was administered in the treatment of outpatients. The drug was given to 50 patients.
Results. Forty percent of patients after treatment demonstrated no depression. In slight and transient suicidal ideation, the drug was ineffective. It exerted far better effect in more acute and more intense suicidal tendencies.
Conclusion. Many authors regard clomipramine as the drug indicated mainly in depressions with psychomotor inhibition with anxiety symptoms. Clomipramine frequently can be regarded as the drug of choice in the treatment of severe endogenous depressions with very intense obsessive-compulsive manifestations.